Distribution of Met and its co-receptors in the human mammary gland remains poorly defined; however, strong expression of Met, ICAM-1, and CD44v6 has been associated with triple-negative breast cancers and correlated with poor prognosis (Charpin et al., 2009; Gastaldi et al., 2010; Ponzo and Park, 2010; Schroder et al., 2011). This evidence concerns the gene ICAM1 and triple-negative breast carcinoma.